- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05540535
Dual-Task Cost in Bilateral Hearing Loss
Dual-Task Cost During Walking in People With Hearing Loss Compared to Normal Hearing
The specific aims of the research study are:
- Compare single-task gait parameters between individuals with hearing loss (HL) and age and education matched controls with normal hearing [normal vs moderate-profound hearing loss (N=23 for each group)]. For that we will compare the primary outcome measure, gait speed, between the groups while participants are walking at a comfortable speed for 1 minute.
- Compare cognitive function between individuals with HL and age and education matched controls. For that we will compare the Neurocognitive Index, derived from a cognitive assessment between groups.
- Compare the effect of a cognitive task while walking on gait parameters between people with HL and age education matched controls with normal hearing. For that we will compare the primary outcome measure, gait speed, between groups while participants are walking at a comfortable speed and counting backwards [serial subtraction of 3] for 1 minute.
- Explore whether cognitive performance (i.e., the Neurocognitive Index) is correlated with Dual task cost (DTC), a deterioration of gait speed while walking and performing concurrent cognitive task [serial subtraction of 3]. The formula to calculate this is the following: DTC = 100 X [(DT - single task)/ single task].
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Procedure and Data Collection:
Participants will be tested at the NYU Physical Therapy department (380 2nd Ave 3rd and 4th floors). Data will be collected by the main researcher who proposes this research work and/or two other lab researchers who are trained to conduct the full protocol. Testing will take between 1.5 to 2 hours and will always start with the cognitive assessment in order to make sure participants will perform at their best and will not be fatigued. All participants will sign an informed consent form. Participates with HL will be tested without hearing aids since recent studies suggest a possible improvement in balance as well as cognition with amplification. Participates will take off their hearing aid at the beginning of testing.
Screening Examination and Descriptive Measures of participants:
The participants will undergo a sensory systems screen including: Early Treatment Diabetic Retinopathy Study (ETDRS) chart confirming normal vision and a 5.07 monofilament screen confirming normal protective sensation at the bottom of their feet. The screening for the vestibular system will include the Dizziness Handicap Inventory (DHI) questionnaire. Screening of the auditory system will be done in participants with HL (as part of their standard care) and for healthy controls who are 60 years of age or older. Participants will also complete the following questionnaires: a demographics and anthropometrics questionnaire, and Activities-Specific Balance Confidence (ABC) to assess balance confidence. To assess the history of falls questions about past falls will be asked. The MoCA will be administered for people with normal hearing, and the HI-MoCA for people with HL in order to assess mild cognitive decline. For people with HL, the Speech, Spatial and Qualities of Hearing Scale (SSQ12), a test assessing function and interference in hearing in daily living, will be conducted. To assess balance and mobility two tests will be conducted: the modified Clinical Test of Sensory Interaction on Balance (mCTSIB) and Time Up and Go Test (TUG). First participants will wear the APDM inertial motion sensors on both feet and waist and will perform the mCTSIB. They will stand with their hands at their sides, feet together and will perform the following sensory conditions for 30 sec: (1) Stand on a firm surface with eyes open, (2) Stand on a firm surface with eyes closed, (3) Stand on a foam with eyes open, and (4) Stand on a foam with eyes closed. Secondly, participants will perform the TUG twice. The best performance in each condition out of the 2 performances will be recorded.
Cognitive Assessment:
Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS) that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory). Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. These tests do not require the ability to hear in order to pass successfully. Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
Gait Assessment:
The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units. Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT). The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number. Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function). The numbers will be recorded for offline processing and the outcome will be the number of correct numbers. Each condition will be performed once, and all conditions will be randomized.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Anat V Lubetzky, PhD
- Phone Number: 212-998-9195
- Email: anat@nyu.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10010
- New York Eye and Ear Infirmary of Mount Sinai
-
New York, New York, United States, 10010
- New York University Physical Therapy Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderate which is defined as a PTA between 41-55dB HL (0.5-4 kHz) in the better ear.
- Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderately-severe which is defined as a PTA between 56-70dB HL (0.5-4 kHz) in the better ear.
- Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical severe which is defined as a PTA between 71-90dB HL (0.5-4 kHz) in the better ear.
- Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical profound which is defined as a PTA above 90+dB HL (0.5-4 kHz) in the better ear.
- No asymmetry of HL which is defined as a difference in PTA that is greater than 15 dB between ears or a difference greater than/equal to 20 dB at two contiguous frequencies or greater than/equal to 10 dB at three contiguous frequencies between ears.
- Adults aged 40 and older with normal hearing which is defined as a PTA below 25dB (0.5-4 kHz) bilaterally.
- Subjects above 65 years of age, with symmetric ARHL in the high frequencies (>3K), with unaided PTA < 40 dB (0.5-4KHz) will be included in the control group as well.
Exclusion Criteria:
- A medical diagnosis of peripheral neuropathy.
- Lack of protective sensation based on the Semmes-Weinstein 5.07 Monofilament Test.
- Visual impairment above 20/63 (NYS Department of Motor Vehicle cutoff for driving) on the Early Treatment Diabetic Retinopathy Study (ETDRS) Acuity Test that cannot be corrected with lenses.
- Active complaint of dizziness
- Conductive HL or air bone gap
- A recent onset of a sudden HL
- Pregnancy
- Any neurological condition interfering with balance or walking (e.g. multiple sclerosis, Parkinson's disease, stroke)
- Acute musculoskeletal pain at time of testing
- Currently seeking medical care for another orthopaedic condition or vestibular rehabilitation
- Take medications that might influence gait or balance (e.g., methylphenidate);
- Inability to read an informed consent form in English.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Bilateral Symmetrical Hearing Loss
Adults aged 40 and older with a clinical diagnosis of bilateral symmetrical moderate, moderately-severe, severe, or profound sensorineural HL in the past three month and on. Moderate hearing will be defined as a PTA between 41-55dB HL (0.5-4 kHz) in the better ear, moderately-severe hearing will be defined as a PTA between 56-70dB HL (0.5-4 kHz) in the better ear, severe HL will be defined as a PTA between 71-90dB HL (0.5-4 kHz) in the better ear and profound HL will be defined as a PTA above 90+dB HL (0.5-4 kHz) in the better ear. Asymmetry of HL will be defined as a difference in PTA that is greater than dB between ears or a difference greater than/equal to 20 dB at two contiguous frequencies or greater than/equal to 10 dB at three contiguous frequencies between ears. |
The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units.
Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT).
The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number.
Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function).
The numbers will be recorded for offline processing and the outcome will be the number of correct numbers.
Each condition will be performed once, and all conditions will be randomized.
Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory).
Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task).
The numbers will be recorded for offline processing and the outcome will be the number of correct numbers.
These tests do not require the ability to hear in order to pass successfully.
Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
|
Control participants with normal hearing.
Normal hearing will be defined as a PTA below 25dB (0.5-4 kHz) bilaterally.
Subjects above 65 years of age, with symmetric ARHL in the high frequencies (>3K), with unaided PTA < 40 dB (0.5-4KHz) will be included in the control group as well.
|
The average speed of gait and spatiotemporal gait parameters would be calculated by the APDM, inertial motion units.
Participants will walk in their normal speed for 1 minute along a corridor, back and forth, with or without performing a cognitive task (single or DT).
The DT condition will include serial subtraction (counting backwards out loud) in jumps of 3 from a random three-digit number.
Randomization of numbers will be done using the excel function generating random numbers (Excel RAND function).
The numbers will be recorded for offline processing and the outcome will be the number of correct numbers.
Each condition will be performed once, and all conditions will be randomized.
Participants will complete a computerized cognitive battery (CNS vital sign; CNSVS)that will include verbal memory, visual memory, Stroop test, shifting attention and 4-part continuous performance (sustained attention and working memory).
Moreover, performance on the single cognitive task (serial subtraction in jumps of 3; measuring working memory and executive function) will also be evaluated while sitting (cognitive single task).
The numbers will be recorded for offline processing and the outcome will be the number of correct numbers.
These tests do not require the ability to hear in order to pass successfully.
Also, there is a need for investigation of cognitive domains such as attention, memory, executive function, and cognitive flexibility in people with HL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait Speed (single task) over 1-minute walk
Time Frame: 60 seconds of a walk.
|
The gait speed while walking for 1 min will be compared between groups.
Normal gait speed will be considered 1.2-1.3
m/sec.
|
60 seconds of a walk.
|
The Neurocognitive Index
Time Frame: 30 minutes of assessment.
|
An average score derived from the average standard scores of the six cognitive domains: Composite Memory, Reaction Time, Cognitive Flexibility, Executive Function, Working Memory and Sustained Attention, representing a form of a global score of the overall neurocognitive status of the subject.
|
30 minutes of assessment.
|
Gait Speed (Dual Task {DT}) over 1-minute walk
Time Frame: 60 seconds of a walk.
|
To test attentional capacity during ambulation using DT paradigm the DT gait speed while walking for 1 min will be compared between the groups.
Moreover, the DTC of the walking speed over 1-minute walk will be calculated as the difference between the scores of the DT and single task 1-minute walking performances to quantify participants' DT ability using the following formula: 100 X (Dual - Single)/Single.
|
60 seconds of a walk.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spatiotemporal gait parameters
Time Frame: 60 seconds of a walk.
|
The following gait parameters will be compared between conditions and groups: stride length, stride time as well as the variability of these gait parameters.
|
60 seconds of a walk.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anat V Lubetzky, PhD, New York University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY-21-01026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Aging
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
Beijing HospitalBGI-ShenzhenCompletedAging | Healthy Aging
-
Northumbria UniversityUniversity of East AngliaSuspendedSleep | Aging | Healthy AgingUnited Kingdom
-
Baskent UniversityCompleted
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
-
Amazentis SAAtlantia Food Clinical TrialsCompletedHealthy | Healthy AgingUnited States
-
University of StirlingCompletedAging | Healthy Aging | Older Adults | AgedUnited Kingdom
Clinical Trials on Gait assessment
-
Afyonkarahisar Health Sciences UniversityRecruiting
-
Delta University for Science and TechnologyUnknownPatellofemoral Pain SyndromeEgypt
-
Baskent UniversityHacettepe UniversityCompletedNeuropathy, Diabetic | Gait Disorder, Sensorimotor | Pain, NeuropathicTurkey
-
Pamukkale UniversityCompleted
-
Gazi UniversityCompleted
-
Hacettepe UniversityCompletedDuchenne Muscular Dystrophy | Gait Disorders, Neurologic | Gait Disorders in ChildrenTurkey
-
University Hospital, LilleRecruitingCognitive DysfunctionFrance
-
University of MinnesotaRecruitingDNA Repair Disorder | Xeroderma Pigmentosum | Cockayne Syndrome | TrichothiodystrophyUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...GOSHCCCompletedTypically Developing Children | Talipes Equino Varus | Paediatric Orthopaedic | Paediatric NeurologicalUnited Kingdom
-
Istituto Ortopedico GaleazziUnknownAged | Asymptomatic ConditionItaly